Rilonacept In Recurrent Pericarditis: Efficacy And Safety Data From An Ongoing Phase 2 Pilot Clinical Trial

Allan Klein,David Lin,Paul Cremer,Saifullah Nasir, Sharon Crugnale,Larisa Collins,Fang Fang,Anna Beutler,John F. Paolini

ARTHRITIS & RHEUMATOLOGY（2019）

引用 10|浏览9

暂无评分

摘要

IL-1α/β predominate in recurrent pericarditis (RP). We present data from an ongoing, open-label Phase 2 study of rilonacept (IL-1α/β trap) in RP.Subjects with symptomatic or corticosteroid (CS)-dependent idiopathic or post-pericardiotomy RP receive subcutaneous rilonacept: 320 mg load, 160 mg

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要